Scienture (SCNX) announced that it has formalized multiple commercial group purchasing organization, GPO, agreements for Arbli Oral Suspension, 10 mg/mL, providing access to more than 2500 healthcare institutions, including hospitals, clinics, nursing homes, specialty pharmacies, long-term care facilities, and ambulatory centers, representing potential penetration into an estimated 20% of the U.S. institutional market while also establishing a broad footprint across long-term care and outpatient facilities.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCNX:
- Scienture Holdings Enters Equity Distribution Agreement
- Scienture formalizes major commercial PBM led by GPO rebate agreement
- Scienture files to sell 2.1M shares of common stock for holders
- Scienture Holdings Completes $3.87 Million Stock Offering
- Scienture prices 3.23M shares at $1.20 in registered direct offering